About: Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies
Creator	Balogun, Simon Ojo, Ademola Ojo, Olusegun Williams, Oyeronke
Source	Medline; PMC
abstract	Although pulmonary fibrosis can occur in the absence of a clear-cut inciting agent, and without a clinically clear initial acute inflammatory phase, it is more commonly associated with severe lung injury. This may be due to respiratory infections, chronic granulomatous diseases, medications, and connective tissue disorders. Pulmonary fibrosis is associated with permanent pulmonary architectural distortion and irreversible lung dysfunction. Available clinical, radiographic, and autopsy data has indicated that pulmonary fibrosis is central to severe acute respiratory distress syndrome (SARS) and MERS pathology, and current evidence suggests that pulmonary fibrosis could also complicate infection by SARS-CoV-2. The aim of this review is to explore the current literature on the pathogenesis of lung injury in COVID-19 infection. We evaluate the evidence in support of the putative risk factors for the development of lung fibrosis in the disease and propose risk mitigation strategies. We conclude that, from the available literature, the predictors of pulmonary fibrosis in COVID-19 infection are advanced age, illness severity, length of ICU stay and mechanical ventilation, smoking and chronic alcoholism. With no proven effective targeted therapy against pulmonary fibrosis, risk reduction measures should be directed at limiting the severity of the disease and protecting the lungs from other incidental injuries.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1155/2020/6175964
bibo:pmid	32850151
has license	cc-by
sha1sum (hex)	9dfefc6cd71d21d514cb91b16ac6de4002304ac8
schema:url	https://doi.org/10.1155/2020/6175964
resource representing a document's title	Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies
has PubMed Central identifier	PMC7439160
has PubMed identifier	32850151
schema:publication	Pulm Med
resource representing a document's body	covid:9dfefc6cd71d21d514cb91b16ac6de4002304ac8#body_text
is schema:about of	named entity 'agent' named entity 'pathogenesis' named entity 'initial' named entity 'strategies' named entity 'illness' named entity 'lung injury' named entity 'pulmonary fibrosis' named entity 'phase' named entity 'current literature' named entity 'pulmonary fibrosis' named entity 'autopsy' named entity 'Although' named entity 'pathogenesis' named entity 'respiratory infections' named entity 'lung dysfunction' named entity 'lungs' named entity 'MERS' named entity 'COVID' named entity 'autopsy' named entity 'infection' named entity 'Fibroblasts' named entity 'antiviral' named entity 'granulocyte-macrophage colony-stimulating factor' named entity 'CD34' named entity 'MERS' named entity 'adaptive immune response' named entity 'connective tissue' named entity 'lung dysfunction' named entity 'pulmonary fibrosis' named entity 'end-stage' named entity 'alveolar spaces' named entity 'acute inflammatory' named entity 'pulmonary function' named entity 'innate immune response' named entity 'acute inflammation' named entity 'TGF-β' named entity 'fibrosis' named entity 'pulmonary fibrosis' named entity 'SARS' named entity 'mechanical ventilation' named entity 'pulmonary fibrosis' named entity 'COVID-19' named entity 'endothelial' named entity 'antiviral agents' named entity 'autophosphorylation' named entity 'mesenchymal progenitor cells' named entity 'PDGF' named entity 'receptor' named entity 'IPF' named entity 'growth factor' named entity 'Experimental studies' named entity 'lymphocytes' named entity 'Lung transplantation' named entity 'TGF-β' named entity 'COVID' named entity '19, 20' named entity 'lung fibrosis' named entity 'chemokine receptors' named entity 'cytokine storm' named entity 'emphysema' named entity 'immune response' named entity 'ICU' named entity 'pathogen-associated molecular patterns' named entity 'pulmonary fibrosis' named entity 'ECM' named entity 'Smoking cessation' named entity 'Pulmonary fibrosis' named entity 'lungs' named entity 'traction bronchiectasis' named entity 'pulmonary function tests' named entity 'Bleomycin-induced pulmonary fibrosis' named entity 'VCAM-1' named entity 'glutathione' named entity 'epithelial cell' named entity 'HB-EGF' named entity 'microbes' named entity 'acute illness' named entity 'Virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software